title: [Efficiency of antiarrhythmic therapy and resistance to it in patients with malignant ventricular tachyarrhythmias: formulation of prognosis].
abstract: OBJECTIVE
  To study feasibility of predicting results of drug antiarrhythmic therapy in patients with malignant ventricular arrhythmias (MVA) basing on the results of clinical and device examinations.
  
  
  METHODS
  136 patients with documented MVA entered the study. 100 patients were in the retrospective analysis group, 36 patients comprised the study group. All the patients underwent physical examination, resting ECG, chest x-ray, radionuclide ventriculography. Intracardiac electrophysiological examination, Holter 24-h ECG monitoring and bicycle exercise provided data for diagnosis of MVA and control over effects of antiarrhythmic drugs. The mathematical model was derived using discriminant analysis.
  
  
  RESULTS
  Significant differences were obtained in patients with positive and negative results of drug testing by the number and recurrence time of ventricular tachycardia (VT) for 3 years, survival, cardiac and sudden death, some other parameters. A mathematic model has been designed which allows prognosis of the results of antiarrhythmic therapy (AAT) in patients with MVA. 7 independent predictors of AAT efficiency are shown: left ventricular ejection fraction, duration of P-Q interval, cardiac failure, left ventricular aneurysm, age, number of VT morphologies, insufficiency of aortic valve. Verification of the model on the study group patients showed that prognostic accuracy of the model was 82%.
  
  
  CONCLUSIONS
  The results of the drug tests predict life span of MVA patients. The developed mathematical model allows prediction of AAT results in such patients before the pharmacological test with accuracy 82-87%. The model can help objectivize indications to use of non-pharmacological methods for each patient basing on prognosis of resistance to drug AAT.
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Nesterenko
authors.forename: S A
authors.initials: SA
authors.lastname: Bakalov
authors.forename: I B
authors.initials: IB
authors.lastname: Krutanov
authors.forename: E B
authors.initials: EB
authors.lastname: Maĭkov
authors.forename: E P
authors.initials: EP
authors.lastname: Mazygula
authors.forename: V A
authors.initials: VA
authors.lastname: Soboleva
authors.forename: S P
authors.initials: SP
authors.lastname: Pasha
authors.forename: V B
authors.initials: VB
authors.lastname: Sergienko
authors.forename: S P
authors.initials: SP
authors.lastname: Golitsyn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D011379:Prognosis; D015635:Radionuclide Ventriculography; D015203:Reproducibility of Results; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents